AstraZeneca’s Fasenra is now approved by the FDA for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype. Fasenra was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma in patients aged 12 and older.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Roche announces CE Mark for Ventana HER2 Rabbit Monoclonal Primary RxDx
- ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Nuvectis says NXP900 demonstrates robust activity in NSCLC
- AstraZeneca’s Enhertu Wins US Approval for Tumours
- ENHERTU approved for treatment of unresectable or metastatic HER2 positive
